• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从复发缓解型多发性硬化症患者的角度理解治疗决策:批判性综合解读。

Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.

机构信息

School of Dentistry, Worsley Building, Leeds LS2 9JT, United Kingdom.

School of Dentistry, Worsley Building, Leeds LS2 9JT, United Kingdom.

出版信息

Mult Scler Relat Disord. 2019 Jan;27:370-377. doi: 10.1016/j.msard.2018.11.016. Epub 2018 Nov 17.

DOI:10.1016/j.msard.2018.11.016
PMID:30476873
Abstract

BACKGROUND

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system that mainly affects young adults. While there is no cure for MS, disease modifying treatments (DMTs) reduce the relapse rate and partial accrual of disability. More effective DMTs may have higher risks including life-threatening infections or secondary autoimmunity. The complexity and novelty of available treatments cause challenges for clinicians when prescribing treatments and for people with MS (PwMS) when deciding what trade-offs they are willing and ready to make.

OBJECTIVE

To explore the experience of people with relapsing remitting MS (PwRRMS) and their perspectives in choosing treatments.

METHODS

Critical interpretive synthesis was employed to review and synthesis the published literature. Eighty-three publications were selected in a multi-step systematic process.

RESULTS

Findings are presented in four interrelated areas: the influence of the clinical evidence-base in decision making; the meaning of DMT efficacy for PwRRMS; the influence of models of decision-making and information acquisition practices in PwRRMS; and the importance of psychosocial dimensions in DMT decision making. Synthesis of the findings revealed that alongside medical and individual reasoning, contextual circumstances play an important role in making treatment decisions.

CONCLUSION

This review identifies and explains the importance of diverse contextual circumstances (clinical, social, psychological) that are important for PwRRMS when making treatment decisions. The findings demonstrate the importance of eliciting, understanding and addressing such contextual factors.

摘要

背景

多发性硬化症(MS)是一种中枢神经系统的慢性炎症性脱髓鞘疾病,主要影响年轻人。虽然目前还无法治愈 MS,但疾病修正治疗(DMT)可降低复发率和残疾的部分累积。更有效的 DMT 可能具有更高的风险,包括危及生命的感染或继发自身免疫。现有治疗方法的复杂性和新颖性给临床医生在开具治疗方案以及 MS 患者在决定愿意和准备做出哪些权衡时带来了挑战。

目的

探讨复发缓解型多发性硬化症(PwRRMS)患者的治疗选择经验及其观点。

方法

采用批判解释性综合方法对已发表的文献进行回顾和综合。通过多步系统过程选择了 83 篇出版物。

结果

研究结果在四个相互关联的领域中呈现:临床证据基础对决策的影响;DMT 疗效对 PwRRMS 的意义;决策模型和信息获取实践对 PwRRMS 的影响;以及 DMT 决策中社会心理维度的重要性。综合分析结果表明,除了医学和个人推理外,背景环境在治疗决策中起着重要作用。

结论

本综述确定并解释了临床、社会和心理等多种背景环境因素对 PwRRMS 治疗决策的重要性。研究结果表明,了解和解决这些背景因素非常重要。

相似文献

1
Understanding treatment decisions from the perspective of people with relapsing remitting multiple Sclerosis: A critical interpretive synthesis.从复发缓解型多发性硬化症患者的角度理解治疗决策:批判性综合解读。
Mult Scler Relat Disord. 2019 Jan;27:370-377. doi: 10.1016/j.msard.2018.11.016. Epub 2018 Nov 17.
2
Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.患者对复发缓解型多发性硬化症中改变疾病修饰治疗方案的决策看法。
Mult Scler Relat Disord. 2020 Nov;46:102507. doi: 10.1016/j.msard.2020.102507. Epub 2020 Sep 19.
3
Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.以患者为中心的决策:运用联合分析确定偏好敏感型治疗选择的风险效益权衡。
J Neurol Sci. 2014 Sep 15;344(1-2):80-7. doi: 10.1016/j.jns.2014.06.030. Epub 2014 Jun 23.
4
Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.欧洲和美国复发缓解型多发性硬化症中医生与患者的治疗决策
Neurodegener Dis Manag. 2018 Dec;8(6):371-376. doi: 10.2217/nmt-2018-0023. Epub 2018 Nov 19.
5
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool.实施多发性硬化症的共享决策:MS-SUPPORT 工具。
Mult Scler Relat Disord. 2023 Dec;80:105092. doi: 10.1016/j.msard.2023.105092. Epub 2023 Oct 21.
6
Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis.沟通对复发缓解型多发性硬化症患者首次治疗决策的影响。
Patient Educ Couns. 2020 May 13. doi: 10.1016/j.pec.2020.05.014.
7
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
8
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.关于复发缓解型多发性硬化症的疾病修正治疗决策:陈述偏好和真实世界选择。
Patient. 2023 Sep;16(5):457-471. doi: 10.1007/s40271-023-00622-1. Epub 2023 Apr 18.
9
The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.德国复发缓解型多发性硬化症患者的患者支持计划对疾病修正治疗依从性的影响:一项非干预性、前瞻性研究。
Adv Ther. 2020 Jun;37(6):2999-3009. doi: 10.1007/s12325-020-01349-3. Epub 2020 Apr 24.
10
Patients experiences with multiple sclerosis disease-modifying therapies in daily life - a qualitative interview study.患者在日常生活中对多发性硬化症治疗药物的体验——一项定性访谈研究。
BMC Health Serv Res. 2021 Oct 22;21(1):1141. doi: 10.1186/s12913-021-07012-z.

引用本文的文献

1
Choosing initial MS therapy; personal, disease, and medication factors.选择初始多发性硬化症治疗方法;个人、疾病及药物因素
Neurotherapeutics. 2025 Jul;22(4):e00582. doi: 10.1016/j.neurot.2025.e00582. Epub 2025 Apr 10.
2
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies.多发性硬化症及疾病修正治疗影响的患者体验
Clinicoecon Outcomes Res. 2025 Mar 15;17:199-215. doi: 10.2147/CEOR.S489929. eCollection 2025.
3
PANORAMA: A 2021 Clinician Survey of Treatment Approaches for People With New Diagnoses of Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
全景调查:2021年英国针对复发缓解型多发性硬化症新诊断患者治疗方法的临床医生调查
Int J MS Care. 2025 Jan 6;27(Q1):1-7. doi: 10.7224/1537-2073.2023-079. eCollection 2025 Jan.
4
Decisional Conflict Regarding Disease-Modifying Treatment Choices Among Patients with Mid-Stage Relapsing-Remitting Multiple Sclerosis.中度复发缓解型多发性硬化症患者在疾病修饰治疗选择上的决策冲突
Patient Prefer Adherence. 2024 Jun 7;18:1163-1171. doi: 10.2147/PPA.S459242. eCollection 2024.
5
Preferences, Adherence, and Satisfaction: Three Years of Treatment Experiences of People with Multiple Sclerosis.偏好、依从性和满意度:多发性硬化症患者三年的治疗经历
Patient Prefer Adherence. 2024 Feb 22;18:455-466. doi: 10.2147/PPA.S452849. eCollection 2024.
6
Anxiety and Perception of Disease Control in Multiple Sclerosis Subjects Treated with Natalizumab.接受那他珠单抗治疗的多发性硬化症患者的焦虑与疾病控制感
J Clin Med. 2023 Dec 19;13(1):13. doi: 10.3390/jcm13010013.
7
Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis.早期复发缓解型多发性硬化症患者的绝望感
Patient Prefer Adherence. 2023 Jun 14;17:1431-1439. doi: 10.2147/PPA.S411069. eCollection 2023.
8
Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.关于复发缓解型多发性硬化症的疾病修正治疗决策:陈述偏好和真实世界选择。
Patient. 2023 Sep;16(5):457-471. doi: 10.1007/s40271-023-00622-1. Epub 2023 Apr 18.
9
Individual Differences in the Patient Experience of Relapsing Multiple Sclerosis (RMS): A Multi-Country Qualitative Exploration of Drivers of Treatment Preferences Among People Living with RMS.复发型多发性硬化症患者体验的个体差异(RMS):对 RMS 患者治疗偏好驱动因素的多国定性探索。
Patient. 2023 Jul;16(4):345-357. doi: 10.1007/s40271-023-00617-y. Epub 2023 Apr 5.
10
Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.基于患者的药物获益-风险评估:开发、完善和验证检索相关研究的内容搜索策略。
J Med Libr Assoc. 2022 Apr 1;110(2):185-204. doi: 10.5195/jmla.2022.1306.